Joshua L. Pollack

Joshua L. Pollack

Auto-generated profile, based on publicly available information

Joshua L. Pollack

UCSF Immunoprofiler Initiative, University of California, San Francisco, San Francisco, California

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Cell Reports
Verified
Journal Article
Open access
MBMikhail Binnewies
Mikhail Binnewies
JPJoshua L. Pollack
Joshua L. Pollack
JRJoshua Rudolph
Joshua Rudolph
SDSubhadra Dash
Subhadra Dash
MAMarwan Abushawish
Marwan Abushawish
VSVenkataraman Sriram
Venkataraman Sriram
Converting checkpoint inhibitor (CPI)-resistant individuals to being responsive requires identifying suppressive mechanisms. We identify TREM2+ tumor-associated macrophages (TAMs) as being correlated with exhausted CD8+ tumor-infiltrating lymphocytes (TILs) in mouse syngeneic tumor models and human solid tumors of multiple histological types. Fc domain-enhanced anti-TREM2 monoclonal antibody (mAb) therapy promotes anti-tumor immunity by elimination and modulation of TAM populations, which leads to enhanced CD8+ TIL infiltration and effector function. TREM2+ TAMs are most enriched in individuals with ovarian cancer, where TREM2 expression corresponds to disease grade accompanied by worse recurrence-free survival. In an aggressive orthotopic ovarian cancer model, anti-TREM2 mAb therapy drives potent anti-tumor immunity. These results highlight TREM2 as a highly attractive target for immunotherapy modulation in individuals who are refractory to CPI therapy and likely have a TAM-rich tumor microenvironment.

4 April 2023
Verified
Other
Open access
AMAdriana M. Mujal
Adriana M. Mujal
ACAlexis J. Combes
Alexis J. Combes
ARArjun A. Rao
Arjun A. Rao
MBMikhail Binnewies
Mikhail Binnewies
BSBushra Samad
Bushra Samad
MKMatthew F. Krummel
Matthew F. Krummel
Supplementary Table from Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer

4 April 2023
Verified
Other
Open access
AMAdriana M. Mujal
Adriana M. Mujal
ACAlexis J. Combes
Alexis J. Combes
ARArjun A. Rao
Arjun A. Rao
MBMikhail Binnewies
Mikhail Binnewies
BSBushra Samad
Bushra Samad
MKMatthew F. Krummel
Matthew F. Krummel
The tumor immune microenvironment (TIME) is commonly infiltrated by diverse collections of myeloid cells. Yet, the complexity of myeloid-cell identity and plasticity has challenged efforts to define bona fide populations and determine their connections to T-cell function and their relationship to patient outcome. Here, we have leveraged single-cell RNA-sequencing analysis of several mouse and human tumors and found that monocyte–macrophage diversity is characterized by a combination of conserved lineage states as well as transcriptional programs accessed along the differentiation trajectory. We also found in mouse models that tumor monocyte-to-macrophage progression was profoundly tied to regulatory T cell (Treg) abundance. In human kidney cancer, heterogeneity in macrophage accumulation and myeloid composition corresponded to variance in, not only Treg density, but also the quality of infiltrating CD8+ T cells. In this way, holistic analysis of monocyte-to-macrophage differentiation creates a framework for critically different immune states.

4 April 2023
Verified
Other
Open access
AMAdriana M. Mujal
Adriana M. Mujal
ACAlexis J. Combes
Alexis J. Combes
ARArjun A. Rao
Arjun A. Rao
MBMikhail Binnewies
Mikhail Binnewies
BSBushra Samad
Bushra Samad
MKMatthew F. Krummel
Matthew F. Krummel
Supplementary Table from Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer

4 April 2023
Verified
Other
Open access
AMAdriana M. Mujal
Adriana M. Mujal
ACAlexis J. Combes
Alexis J. Combes
ARArjun A. Rao
Arjun A. Rao
MBMikhail Binnewies
Mikhail Binnewies
BSBushra Samad
Bushra Samad
MKMatthew F. Krummel
Matthew F. Krummel
Supplementary Table from Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer

4 April 2023
Verified
Other
Open access
AMAdriana M. Mujal
Adriana M. Mujal
ACAlexis J. Combes
Alexis J. Combes
ARArjun A. Rao
Arjun A. Rao
MBMikhail Binnewies
Mikhail Binnewies
BSBushra Samad
Bushra Samad
MKMatthew F. Krummel
Matthew F. Krummel
Supplementary Figure from Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer